The European Medicines Agency's PRIME scheme to accelerate the development of promising drugs that address unmet medical needs has enrolled 19 products in its first year, showing considerable overlap with FDA breakthrough therapy designees but also key differences.

中文翻译：

---

EMA的主要时间

欧洲药品管理局的PRIME计划加快了开发有前途的药物来解决未满足的医疗需求的计划，该计划在第一年就注册了19种产品，与FDA突破性疗法的指定对象有相当大的重叠，但也有一些关键区别。